On October 16th, 2Firsts reported that a manufacturing product of Zhuhai Qisitech (referred to as "Zhuhai Qisi") was included in the "red list" incident. (Click here to read the article).
In response to the incident, Zhuhai Qisi issued a statement today (October 17th), addressing two key points. The specifics of their response are as follows:
1. The product in question does not belong to our company.
2. The management team of Zhuhai Qisi has attached great importance to this matter, conducting a thorough analysis and investigation in a timely manner while actively implementing response measures. As a global aerosol contract manufacturing company, Zhuhai Qisi has always placed product quality and compliance at a high priority. In response to the recent FDA announcement, the company has swiftly initiated an emergency plan, demonstrating a firm attitude and efficient actions in addressing the issue.
Currently, Zhuhai Qisi has decisively stopped production of the products involved, actively contacted customers and brands, and jointly carried out an investigation to cope with this crisis, making every effort to minimize the adverse impact on the market. At the same time, Zhuhai Qisi is actively communicating with the FDA. We also hope that in the future, the FDA will conduct more comprehensive evaluations and considerations for every product from China.
In conclusion, we will continue to enhance communication and cooperation with customers and regulatory authorities, providing reliable and compliant products to the market and consumers with a high sense of responsibility.
(Above is the original response from Zhuhai Qisi)
2Firsts will continue to follow the development of the event and provide updates on relevant news.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
